Corvus Pharma Announces Executive and Board Changes

Ticker: CRVS · Form: 8-K · Filed: Apr 9, 2025 · CIK: 1626971

Corvus Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyCorvus Pharmaceuticals, Inc. (CRVS)
Form Type8-K
Filed DateApr 9, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-of-directors, executive-appointment

TL;DR

Corvus Pharma shakes up leadership with new CMO and board members.

AI Summary

Corvus Pharmaceuticals, Inc. announced on April 8, 2025, changes in its executive and director roles. The company appointed Dr. Richard A. Miller as Chief Medical Officer and elected Ms. Jennifer L. D. Allison and Mr. David M. E. Smith to its Board of Directors. These appointments are effective immediately.

Why It Matters

These leadership changes could signal a strategic shift or a focus on specific areas of growth and development within the company.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

  • Corvus Pharmaceuticals, Inc. (company) — Registrant
  • Dr. Richard A. Miller (person) — Appointed Chief Medical Officer
  • Ms. Jennifer L. D. Allison (person) — Elected to Board of Directors
  • Mr. David M. E. Smith (person) — Elected to Board of Directors
  • April 8, 2025 (date) — Date of earliest event reported

FAQ

Who has been appointed as the new Chief Medical Officer?

Dr. Richard A. Miller has been appointed as the new Chief Medical Officer.

Who were elected to the Board of Directors?

Ms. Jennifer L. D. Allison and Mr. David M. E. Smith were elected to the Board of Directors.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is April 8, 2025.

What is the principal executive office address of Corvus Pharmaceuticals, Inc.?

The address of the principal executive offices is 901 Gateway Boulevard, Third Floor, South San Francisco, CA 94080.

What is the Commission File Number for Corvus Pharmaceuticals, Inc.?

The Commission File Number for Corvus Pharmaceuticals, Inc. is 001-37719.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 9, 2025 by Dr. Richard A. Miller regarding Corvus Pharmaceuticals, Inc. (CRVS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.